The conference focuses on pathophysiology and prevention of gram-negative bacteria. The goal is to bring together leading investigators in the field for in-depth discussions on the current global state of infections that drive antimicrobial resistance (AMR).
Melanoma is a highly heterogeneous disease and is capable of adapting quickly to changing environmental conditions, through the selection of slow-cycling populations with increased intrinsic drug resistance.
The mission of the Philadelphia Drug Discovery Forum is to bring together drug discovery scientists from academia, bio-pharma industry and government to present and discuss their non-proprietary research.
